Dianthus Therapeutics, Inc. /DE/ Proceeds from Stock Options Exercised
Dianthus Therapeutics, Inc. /DE/ (DNTH) reported Proceeds from Stock Options Exercised of $14.86 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromStockOptionsExercised · last filed 2026-08-04
- Dianthus Therapeutics, Inc. /DE/ proceeds from stock options exercised for the quarter ending 2026-06-30 was $10.58M, a 1762.85% increase year-over-year.
- Dianthus Therapeutics, Inc. /DE/ proceeds from stock options exercised for the quarter ending 2026-03-31 was $4.28M, a 13696.77% increase year-over-year.
- Dianthus Therapeutics, Inc. /DE/ proceeds from stock options exercised for the quarter ending 2025-12-31 was $5.07M, a 965.97% increase year-over-year.
- Dianthus Therapeutics, Inc. /DE/ proceeds from stock options exercised for the quarter ending 2025-09-30 was $2.23M, a 653.38% increase year-over-year.
- Dianthus Therapeutics, Inc. /DE/ proceeds from stock options exercised for fiscal 2025 was $7.90M, a 625.05% increase from fiscal 2024.
- Dianthus Therapeutics, Inc. /DE/ proceeds from stock options exercised for fiscal 2024 was $1.09M, a 21700.00% increase from fiscal 2023.
- Dianthus Therapeutics, Inc. /DE/ proceeds from stock options exercised for fiscal 2023 was $5.00K.
- Dianthus Therapeutics, Inc. /DE/ proceeds from stock options exercised for fiscal 2022 was $0.00, a 100.00% decline from fiscal 2021.
| Period end | Proceeds from Stock Options Exercised 3 month | Proceeds from Stock Options Exercised 6 month | Proceeds from Stock Options Exercised 9 month | Proceeds from Stock Options Exercised 12 month |
|---|---|---|---|---|
| 2026-06-30 | $10.58M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | $14.86M 10-Q · filed 2026-08-04 | $19.93M derived: sum of 3 quarters · filed 2026-08-04 | $22.16M derived: sum of 4 quarters · filed 2026-08-04 |
| 2026-03-31 | $4.28M 10-Q · filed 2026-05-05 | $9.35M derived: sum of 2 quarters · filed 2026-05-05 | $11.58M derived: sum of 3 quarters · filed 2026-05-05 | $12.15M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-12-31 | $5.07M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $7.30M derived: sum of 2 quarters · filed 2026-03-09 | $7.87M derived: sum of 3 quarters · filed 2026-08-04 | $7.90M 10-K · filed 2026-03-09 |
| 2025-09-30 | $2.23M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $2.80M derived: sum of 2 quarters · filed 2026-08-04 | $2.83M 10-Q · filed 2025-11-05 | $3.31M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-06-30 | $568.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | $599.00K 10-Q · filed 2026-08-04 | $1.07M derived: sum of 3 quarters · filed 2026-08-04 | $1.37M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-03-31 | $31.00K 10-Q · filed 2026-05-05 | $507.00K derived: sum of 2 quarters · filed 2026-05-05 | $803.00K derived: sum of 3 quarters · filed 2026-05-05 | $850.00K derived: sum of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | $476.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $772.00K derived: sum of 2 quarters · filed 2026-03-09 | $819.00K derived: sum of 3 quarters · filed 2026-03-09 | $1.09M 10-K · filed 2026-03-09 |
| 2024-09-30 | $296.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $343.00K derived: sum of 2 quarters · filed 2025-11-05 | $614.00K 10-Q · filed 2025-11-05 | $614.00K derived: sum of 4 quarters · filed 2025-11-05 |
| 2024-06-30 | $47.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $318.00K 10-Q · filed 2025-08-07 | $318.00K derived: sum of 3 quarters · filed 2025-08-07 | $323.00K derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $271.00K 10-Q · filed 2025-05-12 | $271.00K derived: sum of 2 quarters · filed 2025-05-12 | $276.00K derived: sum of 3 quarters · filed 2025-05-12 | $276.00K derived: sum of 4 quarters · filed 2025-05-12 |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-11 | $5.00K derived: sum of 2 quarters · filed 2025-03-11 | $5.00K derived: sum of 3 quarters · filed 2025-03-11 | $5.00K 10-K · filed 2025-03-11 |
| 2023-09-30 | $5.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $5.00K derived: sum of 2 quarters · filed 2024-11-07 | $5.00K 10-Q · filed 2024-11-07 | $5.00K derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $0.00 10-Q · filed 2024-08-08 | $0.00 derived: sum of 3 quarters · filed 2024-08-08 | |
| 2023-03-31 | $0.00 10-Q · filed 2024-05-09 | $0.00 derived: sum of 2 quarters · filed 2024-05-09 | ||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21 | $0.00 10-K · filed 2024-03-21 | ||
| 2022-09-30 | $0.00 10-Q · filed 2023-11-09 | |||
| 2021-12-31 | $69.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-23 | $494.00K derived: sum of 2 quarters · filed 2023-03-23 | $2.94M derived: sum of 3 quarters · filed 2023-03-23 | $3.36M 10-K · filed 2023-03-23 |
| 2021-09-30 | $425.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $2.88M derived: sum of 2 quarters · filed 2022-11-03 | $3.29M 10-Q · filed 2022-11-03 | $4.47M derived: sum of 4 quarters · filed 2022-11-03 |
| 2021-06-30 | $2.45M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $2.87M 10-Q · filed 2022-08-04 | $4.05M derived: sum of 3 quarters · filed 2022-08-04 | $4.12M derived: sum of 4 quarters · filed 2022-08-04 |
| 2021-03-31 | $418.00K 10-Q · filed 2022-05-16 | $1.59M derived: sum of 2 quarters · filed 2022-05-16 | $1.67M derived: sum of 3 quarters · filed 2022-05-16 | $2.37M derived: sum of 4 quarters · filed 2022-05-16 |
| 2020-12-31 | $1.18M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-08 | $1.25M derived: sum of 2 quarters · filed 2022-03-08 | $1.95M derived: sum of 3 quarters · filed 2022-03-08 | $3.07M 10-K · filed 2022-03-08 |
| 2020-09-30 | $78.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | $771.00K derived: sum of 2 quarters · filed 2021-11-04 | $1.90M 10-Q · filed 2021-11-04 | $2.81M derived: sum of 4 quarters · filed 2021-11-04 |
| 2020-06-30 | $693.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | $1.82M 10-Q · filed 2021-08-05 | $2.73M derived: sum of 3 quarters · filed 2021-08-05 | $2.99M derived: sum of 4 quarters · filed 2021-08-05 |
| 2020-03-31 | $1.12M 10-Q · filed 2021-05-06 | $2.04M derived: sum of 2 quarters · filed 2021-05-06 | $2.29M derived: sum of 3 quarters · filed 2021-05-06 | $2.58M derived: sum of 4 quarters · filed 2021-05-06 |
| 2019-12-31 | $914.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-03 | $1.17M derived: sum of 2 quarters · filed 2021-03-03 | $1.46M derived: sum of 3 quarters · filed 2021-03-03 | $2.02M 10-K · filed 2021-03-03 |
| 2019-09-30 | $257.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $544.00K derived: sum of 2 quarters · filed 2020-11-05 | $1.11M 10-Q · filed 2020-11-05 | $1.11M derived: sum of 4 quarters · filed 2020-11-05 |
| 2019-06-30 | $287.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | $850.00K 10-Q · filed 2020-08-06 | $850.00K derived: sum of 3 quarters · filed 2020-08-06 | |
| 2019-03-31 | $563.00K 10-Q · filed 2020-05-07 | $563.00K derived: sum of 2 quarters · filed 2020-05-07 | ||
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-03 | $29.00K 10-K · filed 2020-03-03 | ||
| 2018-09-30 | $29.00K 10-Q · filed 2019-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |